The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. (Q54655761)

2 June 2018

title

The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. (English)

1 reference

2 June 2018

1 reference

1 reference

1

1 reference

2 June 2018

Estelle Daudigeos-Dubus

5

object named as

Estelle Daudigeos-Dubus

1 reference

2 June 2018

4

Paule Opolon

1 reference

2 June 2018

8

Birgit Geoerger

1 reference

2 June 2018

author name string

Yann Monnet

2

1 reference

2 June 2018

Francoise Farace

3

1 reference

2 June 2018

Abderrahmane Bourredjem

6

1 reference

2 June 2018

Gilles Vassal

7

1 reference

2 June 2018

language of work or name

English

0 references

publication date

8 October 2010

1 reference

2 June 2018

International Journal of Cancer

published in

1 reference

2 June 2018

volume

128

1 reference

2 June 2018

issue

11

1 reference

2 June 2018

page(s)

2748-2758

1 reference

2 June 2018

1 reference

N-myc down-regulates activin A.

21 January 2018

1 reference

Angiogenesis as a target in neuroblastoma.

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts

21 January 2018

1 reference

In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model

21 January 2018

1 reference

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy

21 January 2018

1 reference

Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium.

21 January 2018

1 reference

Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma

21 January 2018

1 reference

The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

21 January 2018

1 reference

High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies

21 January 2018

1 reference

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging

21 January 2018

1 reference

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

Small molecules and targeted therapies in distant metastatic disease.

21 January 2018

1 reference

Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts

21 January 2018

1 reference

A simple way of quantifying immunostained cell nuclei on the whole histologic section

21 January 2018

1 reference

A time-response model for analysis of drug transport and blood flow response during iontophoresis of acetylcholine and sodium nitroprusside

21 January 2018

1 reference

Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib

21 January 2018

1 reference

Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas

21 January 2018

1 reference

Expression of VEGF receptors in cocultured neuroblastoma cells.

21 January 2018

1 reference

Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease

21 January 2018

1 reference

Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors

21 January 2018

1 reference

The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature

21 January 2018

1 reference

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents

21 January 2018

1 reference

Blood and lymph vessels in embryonic tumors

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.25611

1 reference

2 June 2018

1 reference

2 June 2018